Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01148862 · ClinicalTrials.gov registry record · NA
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
A NA study of Type 1 Diabetes Mellitus, sponsored by Medtronic Diabetes.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT01148862 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Medtronic Diabetes. The registered enrollment target is 50 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (64% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT01148862, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Medtronic Diabetes.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise. The study will consist of a total of 50 subjects, age 16 through 60 years with Type 1 Diabetes Mellitus.
Conditions Studied
Interventions
- DEVICE The MiniMed Paradigm® X54 System
Study Locations (5)
California
- AMCR Institute - Escondido
- Stanford University - Stanford
Colorado
- Barbara Davis Center of Childhood Diabetes - Aurora
- Barbara Davis Center for Childhood Diabetes - Denver
Washington
- Rainier Clinical Research Institute - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01148862
The ClinicalTrials.gov registry entry for NCT01148862 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (64% lower). The listed sponsor is Medtronic Diabetes, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which The MiniMed Paradigm® X54 System is the first listed.
NCT01148862 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Washington.
Frequently Asked Questions
What is clinical trial NCT01148862 about?
NCT01148862 is a clinical study titled "Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System". The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise. The study will consist of a total of 50 subjects, age 16 through 60 years with Type 1 Diabetes Melli...
What is the current status of trial NCT01148862?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2010-06. Estimated completion is 2011-11.
What conditions does trial NCT01148862 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT01148862?
The interventions under investigation include: The MiniMed Paradigm® X54 System (DEVICE).
Who is sponsoring clinical trial NCT01148862?
This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01148862 being conducted?
This trial has 5 study locations across California, Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.